• Immunic flagged new post-hoc Phase 2 CALLIPER analyses of vidofludimus calcium in progressive multiple sclerosis, presented at the CMSC Annual Meeting 2026.
• The updated disability-change analyses favored vidofludimus calcium over placebo, suggesting a more complete view of progression and improvement than standard endpoints.
• Patient-reported outcomes showed no negative impact on mood versus placebo over up to 120 weeks, supporting tolerability for long-term use.
• Safety findings remained broadly comparable to placebo, with low discontinuations and no signal suggesting clinically meaningful liver risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605280630PR_NEWS_USPR_____NY69058) on May 28, 2026, and is solely responsible for the information contained therein.